Psyence Biomed, a division of Psyence that specializes in natural psilocybin products, has entered a worldwide exclusive licensing agreement with PsyLabs, a psychedelic active pharmaceutical ingredient development company, for nature-derived psilocybin supply.
Under the agreement, PsyLabs will provide Psyence Biomed with pharmaceutical-grade, EU GMP nature-derived psilocybin for evaluation in clinical trials as a potential treatment for alcohol use disorder (AUD) and other substance use disorders. Psyence Biomed plans to begin with a clinical trial in AUD, while PsyLabs will conduct further development work on the licensed product through 2024 and into 2025.
Analyst QuickTake: Psyence previously partnered with Filament Health for the supply of nature-derived psilocybin. However, this partnership was terminated in July 2024 , as the company sought new partners to support its clinical trials for AUD.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.